by: James Arond-Thomas, MD
In January, 2005 it was reported that cancer has surpassed heart disease – for the first time – as the top killer of Americans younger than 85. In 2002, the most recent year for which information is available, 476,009 Americans younger than 85 died of cancer, compared with 450,637 who died of heart disease. An estimated 1,372,910 new cancer cases and 570,260 cancer deaths are expected this year.
Paclitaxel, a preferred treatment for lung and breast cancers, has a cancer-promoting risk as well….
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin – 8 (IL-8) – a cellular communication molecule that initiates the growth of new blood vessels to feed the growing cancer. In other words, if you fall into this subset of patients, treatment using Paclitaxel alone may not be effective at preventing recurrence.
NF-kB blockade enhances cancer killing ability of Paclitaxel!
IL-8 is under the control of an inflammatory regulating protein called nuclear factor-kappa Beta (NF-kB). When the activation of NF-kB is blocked, IL-8 dries up, much like a faucet that has been turned off. Thus, blocking NF-kB activation enhances the cancer killing ability of Paclitaxel. These results were seen with many types of cancer cells, including lung and esophageal cancer cells.
Paclitaxel is NOT the Only Drug that Promotes Excessive NF-kB
Paclitaxel is but one of a group of drugs that has this unwanted side-effect of activating NF-kB. Other drugs in this group include Doxorubicin, 5-Fluorouracil, Cisplatin, VP-16 (Etoposide), ARA-C, and Methotrexate. In addition, research demonstrates that excessive NF-kB activity contributes to cancer development in the following types of cancers: non-small cell lung cancer, pancreatic, primary liver, head and neck cancer, prostate, breast, esophageal, stomach, colon, Hodgkin’s disease, and multiple myeloma.
Supportive treatment that improves chemotherapy effectiveness…..
Paclitaxel, along with the other NF-kB activating chemotherapeutic drugs, is approved for the treatment of a wide range of cancers. It appears likely that they will continue to be used for the foreseeable future. If you are on (or considering using) Paclitaxel or one of the other drugs in this group to treat cancer, there is a supportive treatment that you need to know about that improves the effectiveness of these drugs and reduces your risk of having a cancer recurrence.
We have a Multi-Dimensional Approach to Reducing Inflammation that Complements and Enhances the Impact of these Drugs!
Paclitaxel, a preferred treatment for lung and breast cancers, has a cancer-promoting risk as well….
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin – 8 (IL-8) – a cellular communication molecule that initiates the growth of new blood vessels to feed the growing cancer. In other words, if you fall into this subset of patients, treatment using Paclitaxel alone may not be effective at preventing recurrence.
NF-kB blockade enhances cancer killing ability of Paclitaxel!
IL-8 is under the control of an inflammatory regulating protein called nuclear factor-kappa Beta (NF-kB). When the activation of NF-kB is blocked, IL-8 dries up, much like a faucet that has been turned off. Thus, blocking NF-kB activation enhances the cancer killing ability of Paclitaxel. These results were seen with many types of cancer cells, including lung and esophageal cancer cells.
Paclitaxel is NOT the Only Drug that Promotes Excessive NF-kB
Paclitaxel is but one of a group of drugs that has this unwanted side-effect of activating NF-kB. Other drugs in this group include Doxorubicin, 5-Fluorouracil, Cisplatin, VP-16 (Etoposide), ARA-C, and Methotrexate. In addition, research demonstrates that excessive NF-kB activity contributes to cancer development in the following types of cancers: non-small cell lung cancer, pancreatic, primary liver, head and neck cancer, prostate, breast, esophageal, stomach, colon, Hodgkin’s disease, and multiple myeloma.
Supportive treatment that improves chemotherapy effectiveness…..
Paclitaxel, along with the other NF-kB activating chemotherapeutic drugs, is approved for the treatment of a wide range of cancers. It appears likely that they will continue to be used for the foreseeable future. If you are on (or considering using) Paclitaxel or one of the other drugs in this group to treat cancer, there is a supportive treatment that you need to know about that improves the effectiveness of these drugs and reduces your risk of having a cancer recurrence.
We have a Multi-Dimensional Approach to Reducing Inflammation that Complements and Enhances the Impact of these Drugs!
Post a Comment